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Abstract 
This study dealing with diabetic type 2 patients to estimate the relationship of gastrin hormone level and 
micralbumin urea  in diabetic patients, a total samples of this study consist of (n=67) of diabetic type 2 patients 
& 25 control . 
      In this study the patients was divided in to three groups according the duration of diabetic,the  percentage of 
patients who have duration of diabetes less than 10 years 34.4% (n=23) as 1st  group, less than 20 years more 
than 10 years 32.8% (n=22) as 2nd group and equal or more than 20 years 32.8% (n=22) as 3rd group ,all 
samples test and control analysis the microalbumin urea levels by the microalbuminuria strips  is MICRAL- 
TEST marker while the gastrin hormone level was analyses by enzyme  immunosorbent assay (ELISA) kit, This 
Enzyme immunosorbent assay kit is designed to detect a specific peptide and its related peptides based on the 
principle of “competitive” enzyme immunoassay. Analysis was carried out using SPSS version 18. Categorical 
variables were presented as frequencies and percentages . The mean differences between gastrin mean of 
microalbuminurea for control and gastrin mean level of microalbuminurea for  all duration groups of type 2 DM, 
there is significant differences between gastrin mean and microalbumin urea levels (t-test=5.199.p<0.001*).  
 
Introduction 
Diabetes mellitus is a chronic illness that requires continuing medical care and ongoing patient self-management 
education and support to prevent acute complications and to reduce the risk of long-term complications. Diabetes 
care is complex and requires multifactorial risk reduction strategies beyond glycemic control. 
          A large body of evidence exists that supports a range of interventions to improve diabetes outcomes ,and it 
is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, 
insulin action, or both. (American Diabetes Association, 2013). 
        It is characterized by hyperglycemia and symptoms of marked hyperglycemia include polyuria, polydipisia, 
weight loss, sometimes with polyphagia, and blurred vision (American Diabetes Association, 2002, 2009). 
        Diabetes mellitus produces inadequate blood glucose control and leads to acute and chronic complications 
(Koda-Kimble and Carlisle, 1995). Acute complications include diabetic ketoacidosis and hyperosmolar 
nonketotic coma (Singh and Marshall, 1995). 
       Chronic complications can involve the kidneys, eyes, nervous system, and cardiovascular system and can be 
classified as either macrovascular or microvascular  (Koda-Kimble and Carlisle, 1995). 
      The diagnosis of type 2 DM often is made 4 to 7 years after the disease process has begun, when most 
patients already have an increased risk of macrovascular processes (Peters and Schriger, 1998), despite this, 20% 
to 25%of patients with DM do not develop macrovascular complications (Koda-Kimble and Carlisle, 1995) and 
20% of patients present with retinopathy; 8%, nephropathy; and 9%, neuropathy Peters and Schriger, (1998). 
        Glomerulonephritis, is a progressive kidney disease caused by angiopathy of capillaries in 
the kidney glomeruli. It is characterized by nephrotic syndrome and diffuse glomerulosclerosis. It is due to 
longstanding diabetes mellitus, and is a prime indication for dialysis in many Western countries. However, of the 
long-term complications associated with DM, diabetic nephropathy is associated with the highest mortality 
(Nathan, 1993). 
       Diabetic nephropathy occurs when proteins deposit in the glomerulus Clark & Lee ( 1995). Thickening of 
the glomerular capillary basement membrane narrows the lumen of the capillaries, impeding blood flow and 
subsequently reducing the filtering surface of the glomerulus (Koda-Kimble &Carlisle, 1995).  
     The principal manifestation of diabetic nephropathy is microalbuminuria and proteinuria is generally regarded 
as a marker for the degree of glomerular damage: the levels of proteinuria correlates well with the prognosis for 
renal function, and interventions that retard the progression of renal disease also reduce proteinuria. 
Foggensteiner et al.,( 2001). 
 
MATERIALS AND METHOD : 
1. Patients and conditions of study 
         We design the plan of this study to measure some parameters in subjects suffer from type 2 diabetes and 
compared it with healthy subjects in the same ages, this parameters include: 
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1- Measurment the level of gastrine hormone. 
2-Measurment the level of microalbumin urea. 
      This study was done in Merjan teaching hospital in Babylon province. The collection of samples were 
conducted during the period from January to February / 2013. The samples taken from 67 patients from the 
diabetic clinic in the mentioned hospital and 25 healthy subjects were taken as control (total persons 92). All 
patients were suffered from type 2 diabetes from which  males and  females. The ages of patients and controls 
were ranges between 20-60 years old. 
2.Collection of blood samples 
       Blood samples were collected often fasting (8-12hr.) from healthy control and diabetic patients by vein 
puncture using 5 ml disposable syringes  in order to estimate the levels of  gastrine hormone by ELISA 
according to the manual (procedure) of DRG International Inc.,USA and  5ml of urine in order to estimate 
the levels of Microalbumine urea by the strip of Accu-Chek Micral test kit .      
    Before the plasma samples were taken to estimate the levels of gastrin hormone the patients and control 
must be do not drink alcohol for 24 hours before the test ,do not eat for 12 hours before the test, do not eat or 
drink anything with caffeine, such as coffee, for 12 hours before the test and do not chew gum or smoke 
cigarettes for 4 hours before the test but they can drink as much water as you want up to 1 hour before the 
test. 
3.Reagents: 
Kit Marker and Origin 
Microalbumine urea Accu-Chek Micral test / Mannheim,Germany 
Gastine hormone DRG International Inc.,USA 
4.Methods : 
A- Gastrin I (Human) ELISA : Porstmann,et al (1992); Avrameas,et al (1992). 
B- Measurement of Microalbuminuria: (The Microalbuminuria Kit is MICRAL-TEST   marker). 
1- The test strip was placed in the urine such that the fluid level was just between the two black bars, making 
sure that it does not touch the side of the vessel in the process. The test strip was withdrawn after 5 
seconds and placed it across the top of the urine vessel. 
2- After 1 minute, the color of the test pad above the inscription “Micral” was compared with the color scale 
on the test strip container label. 
 
RESULTE 
The clinical characteristic features of patients &control group: 
       A total sample of this study consist of (n=67) of diabetic type 2 patients consist of 59.7% (n=40) males and 
40.3% (n=27) females & 25 control , 39.9 % of the total samples have a family history for diabetes mellitus. 
       In this study the percentage of patients who have duration of diabetes less than 10 years 34.4% (n=23), less 
than 20 years more than 10 years 32.8% (n=22), equal or more than 20 years 32.8% (n=22) and control 
(n=25),all diabetic patients divided into three groups dependend on duration of infected with suger, The patients 
who have microalbuminuria 55.2% (n=37). 
       The mean differences between gastrin level of all duration groups of type 2 DM with control by 
microalbumin urea levels, there is significant differences between gastrin mean and microalbumin urea levels . 
Table : Mean differences of gastrin level for each type 2 DM group with control by  microalbumin urea 
levels 
Gastrin level 
 
microalbumin urea N Mean ±S.D t-test P value 
1st group of type 2 DM  Positive 8 146.37 ±43.25 3.394 0.001* Negative 40 75.60 ±55.53 
2nd group of type 2 DM  Positive 8 142.0 ±36.84 3.225 0.002* Negative 39 78.74 ±52.67 
3rd group of type 2 DM  Positive 8 271.12 ±85.59 4.809 <0.001* Negative 39 100.60 ±92.39 
 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.3, No.12, 2013 
 
119 
 
Figure 4.2.12: Mean differences of gastrin for all duration groups of type 2 DM with control by 
microalbumin urea 
DISCUTION : 
         The mean differences between gastrin level of all type 2 DM groups with control by microalbumin urea 
levels, The mean differences between gastrin mean of microalbuminurea for control and gastrin mean level of 
microalbuminurea for  all duration groups of type 2 DM. 
        Although diabetic nephropathy is a very rare cause of kidney failure during childhood, the underlying 
events leading to progressive kidney injury begin during childhood in many patients with type 1 diabetes 
mellitus (Type1DM) and in increasing numbers of children with type 2 diabetes mellitus (Type2DM). The Pima 
Indians of Arizona represent an exceptionally thoroughly studied population suffering from very high rates of 
Type2DM and diabetic nephropathy (Type2DN). This population well illustrates the often inexorable 
progression from glomerular hyperfiltration to microalbuminuria to overt proteinuria and loss of glomerular 
filtration rate (GFR), paralleled by the accumulation of mesangial matrix and basement membrane, glomerular 
hypertrophy, loss of podocytes and eventual glomerular sclerosis and interstitial fibrosis. Structural changes 
quantitatively account for the loss of GFR in T2DN. The mechanism of albuminuria (and its relationship to GFR 
loss) is much less clear. There is strong functional and structural evidence for defects in glomerular size-
selectivity (shunts) due to podocyte pathology, but only beginning at relatively high levels of proteinuria 
(albumin/creatinine ratios > 3000 mg/g). Podocyte loss accompanies, and may underlie, the loss of glomeruli to 
sclerosis. At this point, most evidence in humans suggests detachment of intact podocytes from the glomerular 
basement membrane, rather than apoptosis, as the predominant mechanism of podocyte loss. Lemley.(2008) 
        In this study the result   might be show that the level of gastrin hormone increased in all type 2 DM this 
agree with Emas and Grossman (1969) found that truncal vagotomy caused an increase in the response of 
Heidenhain pouches to a feeding meal and the level of microalbuminurea in urine was increased Lemley.(2008). 
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